Do You Still Need a Pap Smear If You’ve Had a Hysterectomy?

Most people who have had a total hysterectomy for a non-cancerous condition do not need Pap smears afterward. The U.S. Preventive Services Task Force explicitly recommends against cervical cancer screening in women who have had their cervix removed and have no history of high-grade precancerous changes or cervical cancer. But that recommendation hinges on two details many people overlook: exactly which parts were removed during surgery, and why the hysterectomy was performed in the first place. Getting either of those wrong can mean stopping screening when you shouldn’t, or continuing it when there’s no benefit.

The Type of Hysterectomy Changes Everything

A hysterectomy is not one procedure. A total hysterectomy removes the uterus and the cervix. A supracervical (also called subtotal) hysterectomy removes the uterus but leaves the cervix in place. Some people who have had a hysterectomy assume their cervix is gone when it is still there, and that assumption can lead to skipped screenings that were never supposed to stop.

If your cervix is still intact after a supracervical hysterectomy, you need to continue Pap smears on the same schedule as anyone else with a cervix. The risk of cervical stump carcinoma in people with no prior abnormal smears is low, around 0.3%, but it is not zero, and the whole point of screening is catching problems before they become dangerous. Surgeons who perform supracervical hysterectomies are advised to counsel patients about continuing regular Pap smear follow-up.¹

If you are not sure which type of hysterectomy you had, your surgical records or your gynecologist can confirm it. This is worth checking. A surprising number of people don’t know whether their cervix was removed, and medical records sometimes use shorthand that doesn’t make the distinction clear.

When Screening Safely Stops

For people who had a total hysterectomy (cervix removed) for a benign condition like fibroids, heavy bleeding, or endometriosis, and who have no history of cervical intraepithelial neoplasia grade 2 or 3 (the high-grade precancerous changes often abbreviated as CIN 2 or CIN 3) or cervical cancer, the USPSTF recommends stopping Pap smears entirely.² The American College of Obstetricians and Gynecologists and the American Cancer Society align with this position.

The reasoning is straightforward. Pap smears screen for cervical abnormalities caused by persistent HPV infection. Once the cervix is gone and there was no pre-existing disease, the target tissue for that cancer is no longer present. Continuing to screen in this situation doesn’t just waste money; it generates false positives that can lead to unnecessary biopsies and anxiety. A cost-effectiveness analysis found that for people who had a benign hysterectomy, the maximum gain in life expectancy from any vaginal screening strategy was about three weeks, with costs running well above $100,000 per life-year gained and up to $12.8 million for more aggressive screening schedules.³

That doesn’t mean you stop seeing a gynecologist. Routine pelvic exams, discussions about ovarian health, and other preventive care continue regardless of your hysterectomy status. It’s specifically the Pap smear and HPV co-testing that can be dropped.

When Screening Must Continue After Total Hysterectomy

Several situations call for continued vaginal cuff screening even after the cervix has been removed. The common thread is a higher-than-normal risk that HPV-related disease could develop in the remaining vaginal tissue.

Prior high-grade CIN or cervical cancer: If your hysterectomy was performed because of CIN 2, CIN 3, or invasive cervical cancer, HPV may still be present in the vaginal tissue. One study found that women who had a hysterectomy for CIN 3 had an eight-fold greater risk of developing high-grade vaginal intraepithelial neoplasia (VaIN) compared to those whose hysterectomy was for a benign condition.⁴ A case report documented vaginal cancer developing just six months after a complete hysterectomy in a patient whose surgery was complicated by CIN, with HPV DNA levels in vaginal tissue actually increasing after the procedure.⁵
HIV or other immune suppression: Over 30% of HIV-positive women with no pre-hysterectomy history of abnormal Pap tests went on to have abnormal vaginal Pap results after the procedure. Among those who had biopsies, 29% showed high-grade vaginal disease.⁶ Those numbers are striking because these women had no known cervical disease before surgery. Their compromised immune systems left them vulnerable to new HPV-driven changes in the vaginal cuff.
In utero DES exposure: Women whose mothers took diethylstilbestrol during pregnancy face a distinct cancer risk in vaginal and cervical tissue. While the overall risk of developing a DES-related malignancy after age 50 was found to be very low in one cohort (one out of 503 patients), expert recommendations still call for annual vaginal screening that continues beyond age 65 and after hysterectomy, because the clear-cell adenocarcinoma associated with DES is not driven by HPV and would not be caught by HPV testing alone.⁷⁸

If any of these apply to you, the general advice to stop screening does not hold. Your doctor should be tailoring a follow-up plan that accounts for your specific history.

Why Vaginal Cuff Pap Smears Have Limits

Even when post-hysterectomy screening is warranted, it’s worth understanding that vaginal cytology isn’t nearly as reliable as cervical cytology. The Pap smear was designed to sample cells from the cervical transformation zone, a biologically active region where squamous and glandular cells meet and where most HPV-driven cancers arise. After a total hysterectomy, that zone is gone. What’s left is the vaginal cuff, and collecting meaningful cell samples from it is harder.

A study evaluating vaginal Pap test performance in women being monitored after endometrial cancer treatment found a sensitivity of only about 40% for detecting vaginal recurrences, with a positive predictive value of just 7.3%.⁹ In plain terms, the test missed more than half of the actual recurrences and flagged many results that turned out to be nothing. The negative predictive value was reassuringly high (over 98%), meaning a normal result was very likely truly normal. But the test’s ability to catch problems when they existed was poor.

This doesn’t mean vaginal cuff screening is useless for people with genuine risk factors. It means the test has real limitations, and clinicians sometimes supplement it with visual inspection, HPV testing, or biopsy when something looks or feels abnormal during examination. Relying on Pap smears alone for vaginal surveillance misses a lot.

HPV Testing After Hysterectomy

The shift toward HPV-based primary screening in cervical cancer prevention has raised questions about whether HPV testing should replace or supplement vaginal Pap smears for post-hysterectomy patients who still need monitoring. The logic seems appealing: since persistent high-risk HPV drives most vaginal intraepithelial neoplasia after hysterectomy, testing directly for the virus should catch problems earlier.

Research confirms that high-grade VaIN after hysterectomy is strongly associated with persistent high-risk HPV infection.⁴ That association suggests HPV testing has a role. However, no major guidelines currently recommend routine HPV testing of the vaginal cuff in post-hysterectomy patients, partly because the evidence base is thinner than for cervical screening, and partly because the clinical management pathway for a positive vaginal HPV test without visible disease remains unclear.

One retrospective comparison of Pap smears and HPV tests found that for detecting high-grade lesions and squamous cell carcinoma, Pap smears actually had higher sensitivity and specificity than HPV testing (about 97% and 86% for Pap smears versus 88% and 55% for HPV tests). HPV tests were comparable to Pap smears only for low-grade lesions.¹⁰ That study was focused on cervical screening rather than vaginal cuff surveillance specifically, but it illustrates why simply swapping one test for another isn’t always an upgrade. For now, clinicians monitoring high-risk post-hysterectomy patients tend to use both tools rather than choosing one.

HPV Vaccination and Post-Hysterectomy Protection

A question that doesn’t get asked often enough is whether HPV vaccination has any value for someone who has already had a hysterectomy for HPV-related disease. The conventional thinking is that the vaccine prevents initial infection and is most useful before exposure. But for people whose hysterectomy was prompted by high-grade CIN or early cervical cancer, the virus may still be present in the remaining vaginal tissue, and there’s ongoing risk of developing new HPV-related lesions elsewhere in the lower genital tract.

A retrospective analysis examined patients who developed lower genital tract dysplasia after hysterectomy for high-grade CIN or early cervical cancer. The study found that the HPV types covered by the nine-valent vaccine accounted for nearly 95% of the subsequent dysplasia cases. After accounting for patients who had persistent infections with the same HPV type from before surgery (who wouldn’t benefit from vaccination since the virus was already established), the estimated protective effect of vaccination was still around 67%.¹¹

That two-thirds potential protective effect is substantial. The researchers concluded that HPV vaccination should be considered for patients undergoing treatment for HPV-related disease, even if the cervix is being removed. This is an area where guidelines haven’t fully caught up with the emerging data, so it’s worth raising with your doctor if your hysterectomy was HPV-related.

Transgender Men and Screening After Surgery

Transgender men who have had a hysterectomy as part of gender-affirming care face the same biological question as anyone else: was the cervix removed, and was there any prior cervical disease? But they also face unique barriers to screening that can make the situation more complicated.

If a transgender man had a total hysterectomy with cervix removal and no history of high-grade cervical disease, the same guidelines apply: routine Pap smears are not needed. If the cervix was left intact, screening should continue. A case report in the Canadian Medical Association Journal highlighted a transgender man who developed locally advanced cervical cancer, underscoring that clinicians need to consider organ inventory rather than gender identity when determining screening needs.¹²

Testosterone therapy does not eliminate HPV or protect against cervical changes. And the practical reality is that many transgender men avoid gynecological care because of the dysphoria and discomfort it causes, and because healthcare settings don’t always accommodate them well. The result is that screening gaps are common in this population even when screening is clearly indicated. If you are a transgender man with an intact cervix, finding a provider who understands both the clinical need and the personal challenges is important.

The Overscreening Problem

Despite clear guidelines, many people continue getting vaginal Pap smears after a total hysterectomy for benign reasons. Studies have consistently found that a large percentage of post-hysterectomy patients are still being screened when they shouldn’t be. This isn’t harmless.

Every unnecessary Pap smear carries a chance of an abnormal result that turns out to mean nothing. The vaginal cuff is prone to atrophic changes, inflammation, and cellular irregularities that can look suspicious on cytology but aren’t pre-cancerous. These false alarms lead to colposcopies, biopsies, and follow-up appointments that carry their own costs and stress. Research on cervical screening has shown that women who receive a false positive result are significantly more likely to seek additional screening sooner than recommended afterward, suggesting the anxiety from a scare lingers and drives further unnecessary testing.¹³

On a systemic level, the cost-effectiveness numbers are striking. As noted earlier, the most aggressive vaginal screening strategy for post-benign-hysterectomy patients costs over $12 million per life-year gained, far exceeding any accepted threshold for cost-effective medical care.³ Those resources could prevent far more disease if directed toward screening people who actually need it.

If you’ve been getting Pap smears after a benign hysterectomy and your doctor hasn’t discussed stopping, bring it up. Some providers continue ordering the test out of habit, medicolegal caution, or because the patient’s surgical history isn’t front and center in the medical record. A straightforward conversation can usually resolve it.

What to Ask Your Doctor

The decision about post-hysterectomy screening comes down to a few concrete questions you can bring to your next appointment:

Was my cervix removed? If yes, you had a total hysterectomy. If no, you had a supracervical hysterectomy and still need routine cervical screening.
Why was the surgery done? If for fibroids, bleeding, or another benign condition with no history of CIN 2, CIN 3, or cervical cancer, screening can stop. If for cervical disease or cancer, you need ongoing vaginal cuff surveillance.
Do I have any conditions that suppress my immune system? HIV, immunosuppressive medications for organ transplants or autoimmune disease, and similar situations can change the calculus even after a benign hysterectomy.
Was I exposed to DES in utero? This applies to women born roughly between 1940 and 1971, when the drug was prescribed during pregnancy. If you’re not sure, your mother’s medical history or your own records from early gynecological visits might clarify.

Armed with these answers, you and your provider can make a clear, evidence-based decision rather than defaulting to continued screening out of uncertainty. For the large majority of people who had a total hysterectomy for benign disease, dropping the Pap smear isn’t cutting corners. It’s following the evidence to avoid unnecessary procedures while focusing attention where it genuinely matters.